The Department of Defense (DoD) is offering the Amyotrophic Lateral Sclerosis Therapeutic Development Award to support the preclinical assessment of new therapeutics specifically targeting ALS. This grant is for studies that are primarily empirical and product-driven, meaning they should aim to produce tangible therapeutic agents or data. While a hypothesis-driven approach is permissible, it must maintain a clear focus on the development of therapeutics for ALS. The ultimate purpose of this grant is to accelerate the advancement of treatments for Amyotrophic Lateral Sclerosis. It is anticipated that the agents or crucial data generated through this award will directly contribute to moving promising therapies closer to clinical application and patient benefit. This initiative seeks to bridge the gap between early-stage research and therapeutic development.
Opportunity ID: 53733
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-10-ALSRP-TDA |
| Funding Opportunity Title: | DoD Amyotrophic Lateral Sclerosis Therapeutic Development Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Apr 14, 2010 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Aug 04, 2010 |
| Current Closing Date for Applications: | Aug 04, 2010 |
| Archive Date: | Sep 03, 2010 |
| Estimated Total Program Funding: | $4,800,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The Therapeutic Development Award supports the preclinical assessment of therapeutics for ALS. The proposed studies are expected to be empirical in nature and product-driven, but may have a hypothesis-driven approach, provided the focus is on therapeutics. It is anticipated that the agents and/or data generated from these awards will lead to the advancement of therapeutics for ALS. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil
eReceipt HELP: 301-682-5507; help@cdmrp.org Email:cdmrp.pa@amedd.army.mil |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 53733 Full Announcement-1 -> fy10 cdmrp detailed budget and justification form-1.pdf
Folder 53733 Full Announcement-1 -> fy10 cdmrp biosketch-2.pdf
Folder 53733 Full Announcement-1 -> alsrp_fy10 tda pa_gg.pdf
Packages
| Agency Contact Information: | PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil eReceipt HELP: 301-682-5507; help@cdmrp.org Email: cdmrp.pa@amedd.army.mil |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00017998 | Apr 14, 2010 | Aug 04, 2010 | View |
Package 1
Mandatory forms
53733 RR_SF424_1_2-1.2.pdf
53733 PerformanceSite_1_4-1.4.pdf
53733 RR_KeyPersonExpanded_1_2-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
